The North America Minimally Invasive Glaucoma Surgery (MIGS) Devices Market would witness market growth of 29.5% CAGR during the forecast period (2018 ? 2024). Minimally invasive glaucoma surgery (MIGS) devices are used to treat glaucoma to provide a safer and lesser invasive means of reducing intraocular pressure (IOP), as compared to conventional glaucoma surgery devices. MIGS devices would be most preferred surgical modality during the forecast period to treat glaucoma. It limits the dependency on conventional medications as well as cuts the complications associated with traditional procedures. Glaucoma is a progressive disease and is the major cause of irreversible blindness with an estimated burden to rise 111.8 million by 2040. This has increased the demand for MIGS devices in the treatment of glaucoma. The factors driving the market include rapid rise in geriatric population, who are more prone to ophthalmology diseases such as glaucoma and cataract. The novel paradigm of glaucoma therapy by using MIGS devices will aspire to a much reduced dependence on topical medication. In addition, increasing preference of surgeons for MIGS is adding boost to the market growth.

On the basis of Surgery, the market is segmented into Glaucoma in Conjunction with Cataract and Stand Alone Glaucoma. Target is categorized into Trabecular Meshwork, Suprachoroidal Space and Other Targets. On the basis of Product, the market is segmented into MIGS Stents, MIGS Shunts and Other Products. The End Users covered under the report are Eye Hospitals, Ophthalmology Clinics and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America. The market research report covers the analysis of key stake holders of the market.